Plain-English translation of NCT07695207 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called taken by mouth alongside ranibizumab, which is an eye injection you may already receive for wet macular degeneration. Half of the 266 participants will receive plus the standard injection, and half will receive a placebo pill plus the same injection. The goal is to see whether the medication helps people keep their vision better over 12 months.
Wet macular degeneration is a serious eye condition that can lead to vision loss, and current treatments help but may not be enough for everyone. This trial exists to find out whether this medication could improve results when combined with the standard treatment.
You likely qualify if…
You likely don't qualify if…
Over 12 months, you will take either tablets or a placebo tablet daily by mouth, along with your regular ranibizumab eye injections. You will have multiple clinic visits for eye exams, imaging tests (like OCT scans and angiography), and vision checks to see how well the treatment is working. Your eye doctors will carefully monitor your vision and eye health throughout the study to ensure your safety.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
South Korea